Cencora, Inc. (NYSE:COR) Receives $277.90 Consensus Price Target from Analysts

Shares of Cencora, Inc. (NYSE:COR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven analysts that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $277.90.

Several analysts have recently issued reports on COR shares. UBS Group increased their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Barclays raised their target price on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Robert W. Baird raised their target price on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company raised their target price on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a report on Wednesday, January 29th.

Cencora Trading Up 0.2 %

COR stock traded up $0.48 during mid-day trading on Friday, hitting $246.86. 1,076,644 shares of the company were exchanged, compared to its average volume of 1,476,687. The company has a quick ratio of 0.53, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a market capitalization of $47.71 billion, a P/E ratio of 35.11, a PEG ratio of 1.49 and a beta of 0.49. The business has a fifty day simple moving average of $238.86 and a 200-day simple moving average of $237.03. Cencora has a 12-month low of $214.77 and a 12-month high of $262.26.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts predict that Cencora will post 15.36 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Friday, February 14th. Cencora's dividend payout ratio (DPR) is 31.29%.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the firm's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. This trade represents a 6.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock valued at $17,790,912 over the last 90 days. 10.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cencora

A number of hedge funds have recently added to or reduced their stakes in the stock. Czech National Bank increased its holdings in shares of Cencora by 12.6% during the third quarter. Czech National Bank now owns 35,536 shares of the company's stock valued at $7,998,000 after purchasing an additional 3,990 shares during the period. Dynamic Advisor Solutions LLC grew its holdings in Cencora by 15.2% during the third quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company's stock worth $262,000 after acquiring an additional 154 shares during the period. LVW Advisors LLC grew its holdings in Cencora by 14.2% during the third quarter. LVW Advisors LLC now owns 3,666 shares of the company's stock worth $825,000 after acquiring an additional 456 shares during the period. Iowa State Bank acquired a new position in Cencora during the third quarter worth about $1,390,000. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its holdings in Cencora by 33.7% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 27,375 shares of the company's stock worth $6,160,000 after acquiring an additional 6,900 shares during the period. 97.52% of the stock is currently owned by institutional investors.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.